1,185 results on '"Ariceta, Gema"'
Search Results
2. Addressing the psychosocial aspects of transition to adult care in patients with cystinosis
3. Correction to: Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
4. A better future for children with STEC-hemolytic uremic syndrome: news from Argentina
5. Sodium intake and urinary losses in children on dialysis: a European multicenter prospective study
6. Favorable Outcome After Single-kidney Transplantation From Small Donors in Children: A Match-controlled CERTAIN Registry Study
7. Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab
8. Renal and Extrarenal Phenotypes in Patients With HNF1B Variants and Chromosome 17q12 Microdeletions
9. Ex vivo C5b-9 Deposition Test to Monitor Complement Activity in Clinical and Subclinical Atypical Hemolytic Uremic Syndrome and in Transplantation-Associated Thrombotic Microangiopathy
10. Metabolic Acidosis Is Associated With an Accelerated Decline of Allograft Function in Pediatric Kidney Transplantation
11. The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
12. Multi-population genome-wide association study implicates immune and non-immune factors in pediatric steroid-sensitive nephrotic syndrome
13. ePHex: a phase 3, double-blind, placebo-controlled, randomized study to evaluate long-term efficacy and safety of Oxalobacter formigenes in patients with primary hyperoxaluria
14. Isolation and characterization of exosome-enriched urinary extracellular vesicles from Dent’s disease type 1 Spanish patients
15. Aislamiento y caracterización de vesículas extracelulares enriquecidas en exosomas en pacientes españoles con enfermedad de Dent 1
16. Autosomal Dominant Tubulointerstitial Kidney Disease
17. Hyperparathyroidism Is an Independent Risk Factor for Allograft Dysfunction in Pediatric Kidney Transplantation
18. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2
19. #243 Characteristics and safety in patients with atypical haemolytic uraemic syndrome switching to ravulizumab from eculizumab: a global registry analysis
20. #2245 ECYSCO, a European cystinosis cohort
21. Renal antiporter ClC-5 regulates collagen I/IV through the β-catenin pathway and lysosomal degradation
22. Characterization of patients with aHUS and associated triggers or clinical conditions: A Global aHUS Registry analysis
23. Ex vivo C5b-9 deposition test to monitor complement activity in clinical and subclinical aHUS and in transplantation-associated thrombotic microangiopathy (TA-TMA)
24. Refining Kidney Survival in 383 Genetically Characterized Patients With Nephronophthisis
25. Oral Coenzyme Q10 supplementation leads to better preservation of kidney function in steroid-resistant nephrotic syndrome due to primary Coenzyme Q10 deficiency
26. Variation of the clinical spectrum and genotype-phenotype associations in Coenzyme Q10 deficiency associated glomerulopathy
27. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis
28. Heterogeneity is a common ground in familial hypomagnesemia with hypercalciuria and nephrocalcinosis caused by CLDN19 gene mutations
29. Molecular aspects and long-term outcome of patients with primary distal renal tubular acidosis
30. Switching from immediate- to extended-release cysteamine in patients with nephropathic cystinosis: from clinical trials to clinical practice
31. Refining genotype–phenotype correlations in 304 patients with autosomal recessive polycystic kidney disease and PKHD1 gene variants
32. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
33. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
34. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria
35. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia
36. Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders
37. An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis
38. Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis.
39. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
40. Recommendations for the management of renal involvement in tuberous sclerosis complex
41. Recomendaciones de manejo de la afectación renal en el complejo esclerosis tuberosa
42. IDENTIFICATION OF MODIFIER GENE VARIANTS OVERREPRESENTED IN FAMILIAL HYPOMAGNESEMIA WITH HYPERCALCIURIA AND NEPHROCALCINOSIS PA-TIENTS WITH A MORE AGGRESSIVE RENAL PHENOTYPE
43. Changes in vascular access profile for pediatric hemodialysis patients over time: A registry-based study from Catalonia
44. Hemolytic Uremic Syndrome
45. The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results
46. Rapid response in the COVID-19 pandemic: a Delphi study from the European Pediatric Dialysis Working Group
47. Autosomal Dominant Tubulointerstitial Kidney Disease
48. Intracranial Hypertension in Cystinosis Is a Challenge: Experience in a Children’s Hospital
49. Clinical profiles and patterns of kidney disease progression in C3 glomerulopathy
50. Risk Factors for Early Dialysis Dependency in Autosomal Recessive Polycystic Kidney Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.